Core Viewpoint - The vaccine industry is showing significant growth in the first three quarters of the year, with various vaccine types, including circular, diarrhea, brucellosis, and cat trivalent vaccines, continuing to perform well [1][2] Vaccine Batch Issuance - In the first three quarters, most vaccine types have seen substantial year-on-year growth, with specific increases in pig vaccines such as foot-and-mouth disease (+9.1%), circular vaccine (+29.5%), pseudorabies vaccine (+27.0%), and swine fever vaccine (+17.7%) [1] - Poultry vaccines like avian influenza trivalent vaccine (+9.6%) and Newcastle disease vaccine (+12.4%) also showed stable growth, while brucellosis vaccine experienced a remarkable increase of +60.2% [1][2] - Pet vaccines, particularly domestic rabies vaccine (+22.8%) and domestic cat trivalent vaccine (+74.4%), have maintained high growth rates [1] Factors Driving Growth - The growth in pig vaccines is attributed to multiple factors, including farming profitability, increased pig slaughter rates, and the introduction of new products [2] - The poultry vaccine sector continues to grow steadily, while the brucellosis vaccine benefits from the ongoing launch of new products [2] Veterinary Drug Raw Materials - As of October 22, the Veterinary Pharmaceutical Index (VPI) stands at 69.29, reflecting a 0.1% increase from the end of September and a 6.4% increase year-on-year [3] - The VPI index has shown a positive trend in October, with an average of 69.33, marking a 0.9% increase from September [3][4] Price Trends and Market Dynamics - The price of veterinary raw materials has been on the rise due to tightened supply and increased demand from large orders, particularly for products like tylosin [4] - The overall price increase in veterinary raw materials is driven by a combination of cost factors, corporate strategies, and market demand [4] Investment Recommendations - The industry is gradually recovering from a downturn, with a focus on undervalued companies that exhibit both elasticity and certainty [5] - Companies that have shown strong performance typically possess innovative qualities in product development, marketing strategies, or capital operations [6] - Recommended companies for investment include Ruipu Biological (300119.SZ), Kexin Biological (688526.SH), and others [6]

Investment Rating - The report maintains a "Recommendation" rating for the animal health industry, expecting the industry index to outperform the benchmark index by more than 5% in the next 3-6 months [2][82]. Core Insights - The animal health industry has shown significant growth in vaccine issuance, with most vaccine varieties experiencing year-on-year increases in the first three quarters of the year. Key vaccines such as porcine epidemic diarrhea, porcine circovirus, and others have demonstrated strong performance [9][12]. - The Veterinary Product Index (VPI) has shown a continued upward trend in October, indicating a recovery in raw material prices for veterinary drugs after a period of decline [3][58]. - The report highlights that the industry is gradually emerging from a low point, with a focus on undervalued companies that exhibit both elasticity and certainty in their performance [71][72]. Summary by Sections Vaccine Issuance - Cumulative data from January to September shows that most vaccine varieties have experienced significant year-on-year growth, particularly in porcine vaccines, with increases of 9.1% for foot-and-mouth disease vaccine, 29.5% for porcine circovirus vaccine, and 60.2% for brucellosis vaccine [9][12]. - The report notes that the growth in vaccine issuance is driven by multiple factors, including farming profitability, increased slaughter rates, and the introduction of new products [13][14]. Raw Material Prices - As of October 22, the VPI stands at 69.29, reflecting a 0.1% increase from the end of September and a 6.4% increase year-on-year. This marks a recovery after three consecutive months of decline [58][61]. - The report indicates that the prices of most veterinary raw materials have improved, with significant increases noted for products like Tylosin and Amoxicillin [59][61]. Investment Recommendations - The report suggests focusing on companies that have shown resilience and innovation, such as Reap Bio, Kexin Bio, and others, as they are expected to perform well in the recovering market [71][73]. - It emphasizes that the competitive landscape is shifting, with larger companies likely to outperform smaller ones, leading to potential consolidation in the industry [72][73].

Group 1 - The core viewpoint of the report indicates that the majority of vaccine varieties have experienced significant year-on-year growth from January to August, particularly in the pet vaccine sector, with domestic rabies vaccine and cat trivalent vaccine increasing by 16.8% and 78.9% respectively [1][2] - In the pig vaccine category, the economic product circular vaccine and mandatory vaccines such as pseudorabies and swine fever vaccines have shown rapid growth, attributed to sustained breeding prosperity and increased pig inventory [1][3] - The VPI index for veterinary raw materials has rebounded by approximately 2.1% by the end of September, following a three-month decline, driven by supply-side tightening and large downstream orders [4][5] Group 2 - The report highlights that the growth in vaccine issuance is supported by multiple factors including breeding prosperity, inventory growth, disease prevalence, and the introduction of new products [3][6] - The increase in prices for veterinary raw materials is primarily due to supply-side changes and improved market competition, with specific products like florfenicol benefiting from a more favorable supply environment [5][6] - The industry is gradually emerging from a downturn, with a focus on undervalued companies that exhibit both elasticity and certainty, suggesting a positive outlook for the sector [7]